Enfermedad de Behçet ocularEstudio retrospectivo

  1. RM Torres
  2. B Yáñez
  3. JM Herreras
  4. M Calonge
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2004

Volume: 79

Issue: 12

Pages: 599-604

Type: Article

DOI: 10.4321/S0365-66912004001200005 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Sustainable development goals

Abstract

Objective: To study clinical features, visual prognosis and response to immunosuppressive drugs in patients with ocular Behçet Disease (BD). Patients and methods: clinical data of 17 patients (33 eyes) were retrospectively reviewed from May 1996 to May 2003. Results: The male/female ratio was 12/5. The commonest manifestations were oral ulceration (100%) and skin lesions (88%). Anterior uveitis was present in 59%, posterior uveitis was in 76% and panuveitis was in 88.1%. Visual acuity improved in 11 (33.3%) eyes, remind stable in 18 (54.5%) eyes and four (12.1%) eyes lost two or more lines. Main drug therapy consisted of colchicine and cyclosporine (59%). Seven patients had received three drugs simultaneously. Conclusions: BD can lead to an irreversible visual loss; however, the visual prognosis is good (85%) if immunosuppressor treatment is implemented.

Bibliographic References

  • Mochizuki, M, Akduman, L, Nussenblatt, RB.. (1996). Ocular Infection & Immunity. Mosby. St. Louis.
  • Zafirakis, P, Foster, S.. (2002). Diagnosis and Treatment of Uveitis. W.B Saunders Company. Philadelphia.
  • (1990). Criteria of Behcet´s disease. Lancet. 335. 1078-1080
  • Muhaya, M, Lightman, S, Ikeda, E, Mochizuki, M, Shaer, B, McCluskey, P. (2000). Behcet’s disease in Japan and in Great Britain: a comparative study. Ocul Immunol and Inflamm. 8. 141-148
  • Sakane, T, Takeno, M, Suzuki, N, Inaba, G.. (1999). Behcet´s disease. N Eng J Med. 341. 1284-1291
  • Matsuo, T, Itami, M, Nakagawa, H, Nagayama, M.. (2002). The incidence and pathology of conjunctival ulceration in Behcet´s syndrome. Br J Ophthalmol. 86. 140-143
  • Baixauli, A, Calvo, J, Tamarit, JJ, Campos, C, Garcia, S, Herrera, A.. (2001). Enfermedad de Behcet: estudio retrospectivo. An Med Interna. 18. 405-410
  • Carreño Perez, L.. (2001). Enfermedad de Behcet. An Med Interna. 18. 401-404
  • Kilmartin, DJ, Finch, A, Acheson, RW.. (1997). Primary association of HLA-B51 with Behcet´s disease in Ireland. Br J Ophthalmol. 81. 649-653
  • Vidaller Palacin, A, Robert Olalla, J, Sanuy Jimenez, B, Rufi Rigau, G, Foloch Civit, J, Charte Gonzalez, A.. (2002). Tratamiento de la enfermedad de Behçet. An Med Int. 19. 594-598
  • Kotake, S, Furudate, N, Sasamoto, Y, Yoshikawa, K, Okamoto, T, Goda, C. (1995). Clinical study on patients with Behcet´s disease in Hokkaido. Ocular Immunology and Inflammation. 3. 237-241
  • Ando, K, Fujino, Y, Hijikata, K, Izawa, Y, Masuda, K.. (1999). Epidemiological features and visual prognosis of Behcet’s disease. Jpn J Ophthalmol. 43. 312-317
  • Sloper, CM, Powell, RJ, Dua, HS. (1999). Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 106. 723-728
  • Toker, E, Kazokoglu, H, Acar, N.. (2002). High dose intravenous steroid therapy for severe posterior segment uveitis in Behcet´s disease. Br J Ophthalmol. 86. 521-523
  • Miserocchi, E, Baltatzis, S, Ekong, A, Roque, M, Foster, CS.. (2002). Efficacy and safety of chlorambucil in intractable non-infectious uveitis: The Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 109. 137-142
  • Kotter, I, Eckstein, AK, Stubiger, N, Zierhut, M.. (1998). Treatment of ocular symptoms of Behcet´s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 82. 488-494
  • Demiroglu, H, Ozcebe, OI, Barista, I, Dundar, S, Eldem, B.. (2000). Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet´s disease: a randomised trial. Lancet. 355. 605-609
  • Sfikakis, PP, Theodossiadis, PG, Katsiari, CG, Kaklamanis, P, Markomichelakis, NN.. (2001). Effect of infliximab on sight-threatening panuveitis in Behcet´s disease. Lancet. 358. 295-296
Data source: Dialnet